Literature DB >> 12032903

Treatment of Scedosporium apiospermum brain abscesses with posaconazole.

Ingo K Mellinghoff1, Drew J Winston, Geoffrey Mukwaya, Gary J Schiller.   

Abstract

A 41-year-old man with acute lymphoblastic leukemia developed multiple Scedosporium apiospermum brain abscesses. The infection progressed despite neurosurgical drainage and treatment with itraconazole, amphotericin B, and ketoconazole, but the brain abscesses completely resolved after treatment with posaconazole alone.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12032903     DOI： 10.1086/340522

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  23 in total

Review 1.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.

Authors:  Fèlix Gilgado; Carolina Serena; Josep Cano; Josepa Gené; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

3.  Treatment options in emerging mold infections.

Authors:  Patricia Muñoz; Jesús Guinea; Emilio Bouza
Journal:  Curr Infect Dis Rep       Date:  2008-11       Impact factor: 3.725

4.  Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.

Authors:  Mariana Castanheira; Lalitagauri M Deshpande; Andrew P Davis; Paul R Rhomberg; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  Experimental murine scedosporiosis: histopathology and azole treatment.

Authors:  M Mar Rodríguez; F Javier Pastor; Valentina Salas; Enrique Calvo; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

6.  Efficacy of posaconazole in a murine model of central nervous system aspergillosis.

Authors:  Jackie K Imai; Gaurav Singh; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Antifungal therapy of murine Aspergillus terreus infection.

Authors:  John R Graybill; Steve Hernandez; Rosie Bocanegra; Laura K Najvar
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 8.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

9.  Disposition of posaconazole following single-dose oral administration in healthy subjects.

Authors:  Philip Krieter; Brian Flannery; Timothy Musick; Mark Gohdes; Monika Martinho; Rachel Courtney
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 10.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.